Senti Biosciences, Inc. — fact timeline

Senti Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $4.2 million, or $0.14 per basic and diluted share.

“Net loss was $4.2 million, or $0.14 per basic and diluted share, for the first quarter of 2026”

Senti Biosciences, Inc. issued Senior Secured Convertible Notes convertible into shares of common stock of the Company, Senti Biosciences, and Senti Holdings of convertible note to Celadon Partners SPV 24 for $40.0 million aggregate principal amount (initial tranche of $10.0 million).

“On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.”

Senti Biosciences, Inc. entered into Securities Purchase Agreement with an entity affiliated with Celadon Partners SPV 24 valued at $40.0 million (effective 2026-04-27).

“On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.”

Senti Biosciences, Inc. incurred convertible notes of $10.0 million with Celadon Partners SPV 24 affiliate at will not bear any interest unless an event of default has occurred maturing six months after the closing date of the Initial Notes.

“the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions”

Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Biosciences amended and restated its bylaws to simplify them after becoming a wholly-owned subsidiary (effective 2026-04-24).

“Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.”

Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Holdings adopted an Amended and Restated Certificate of Incorporation, and Senti Biosciences adopted a Third Amended and Restated Charter to simplify its certificate of incorporation after becoming a wholly-owned subsidiary (effective 2026-04-24).

“Upon consummation of the Reorganization, the Amended and Restated Certificate of Incorporation of Senti Biosciences Holdings (the “Amended and Restated Certificate of Incorporation”) and the Amended and Restated Bylaws of Senti Biosciences Holdings (the “Amended and Restated Bylaws”) are the same as the second amended and restated certificate of incorporation and amended and restated bylaws of Senti Biosciences in effect immediately prior to consummation of the Reorganization, respectively, other than changes permitted by Section 251(g) of the DGCL.”

Senti Biosciences, Inc. amended A&R New Enterprise Designation Agreement with New Enterprise Associates 15, L.P. (effective 2026-04-24).

“Senti Biosciences amended and restated that certain Designation Agreement by and between Senti Biosciences and New Enterprise Associates 15, L.P. (“New Enterprise”), dated December 2, 2024 (as amended and restated, the “A&R New Enterprise Designation Agreement”)”

Senti Biosciences, Inc. amended A&R Celadon Designation Agreement with Celadon Partners SPV 24 (effective 2026-04-24).

“Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)”

Senti Biosciences, Inc. entered into Assignment and Assumption Agreement with Senti Biosciences Holdings (effective 2026-04-24).

“per share (“Senti Biosciences Holdings Common Stock”), issued in connection with the Merger are deemed registered under Section 12(b) of the Exchange Act as the common stock of the successor issuer.”

Senti Biosciences, Inc. entered into Agreement and Plan of Merger with Merger Sub (effective 2026-04-24).

“On April 24, 2026, Senti Biosciences completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.”

Senti Biosciences, Inc. reported the year ended December 31, 2025 results: net income Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share, EPS $2.73 per share.

“Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results”

Senti Biosciences, Inc. entered into Letter Agreement with GeneFab, LLC valued at outstanding base rent of $1,374,005 may be satisfied via cash prepayment credit for work or services (effective 2025-09-01).

“On March 17, 2026, the Company entered into a letter agreement with GeneFab (the “Letter Agreement”), effective as of the Effective Date. The Letter Agreement provides, among other things, that the outstanding base rent of $1,374,005 owed by GeneFab to the Company may be satisfied, in whole or in part, through a cash prepayment credit to be applied toward work or services to be performed by GeneFab for the Company under a separate arrangement, that the Company may access such prepayment credit as of the Effective Date and that any unpaid portion must be paid in immediately available funds by September 1, 2026.”

Senti Biosciences, Inc. amended First Amendment to Landlord's Consent to Sublease with 1430 South Loop Owner, LLC and GeneFab, LLC valued at Landlord consented to Sublease Amendment in consideration for $1.0 million Reduction Fee (effective 2025-09-01).

“On March 17, 2026, the Company entered into a First Amendment to Landlord’s Consent to Sublease (the “Consent Amendment”) among the Company, the Landlord and GeneFab, which was effective as of the Effective Date. Pursuant to the Consent Amendment, the Landlord consented to the Sublease Amendment in consideration for the payment by the Company or GeneFab of $1.0 million to the Landlord (the “Reduction Fee”).”

Senti Biosciences, Inc. amended First Amendment to Sublease with GeneFab, LLC valued at subleased premises reduced to ~45,955 rentable square feet; base rent, operating expenses, taxes and (effective 2025-09-01).

“On March 17, 2026, the Company entered into a First Amendment to Sublease (the “Sublease Amendment”), which amended and restated that certain Sublease Agreement dated August 7, 2023 (the “Original Sublease Agreement” and the Original Sublease Agreement as amended by the Sublease Amendment, the “Amended Sublease”) by and between the Company, as sublandlord, and GeneFab, LLC (“GeneFab”) as subtenant. Pursuant to the Sublease Amendment, which was effective as of the Effective Date, the subleased premises were reduced to approximately 45,955 rentable square feet as of the Effective Date.”

Senti Biosciences, Inc. amended First Amendment to Lease with 1430 South Loop Owner, LLC valued at reduction of leased premises from ~91,910 to ~45,955 rentable square feet; monthly base rent reduced (effective 2025-09-01).

“On March 17, 2026, Senti Biosciences, Inc. (the “Company”) entered into a First Amendment to Lease (the “Lease Amendment”), which amended that certain Research and Development and Laboratory Lease Agreement dated June 3, 2021 (the “Original Lease Agreement” and the Original Lease Agreement as amended by the Lease Amendment, the “Amended Lease”) by and between the Company and 1430 South Loop Owner, LLC (the “Landlord”) for the Company’s premises located at 1430 Harbor Bay Parkway, Alameda, California. Pursuant to the Lease Amendment, which is effective as of September 1, 2025 (the “Effective Date”), the Company has agreed to a reduction of the leased premises from approximately 91,910 rentable square feet to approximately 45,955 rentable square feet as of the Effective Date.”

Feng Hsiung was appointed as Class III Director at Senti Biosciences, Inc..

“On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.”

Jay Cross was appointed as Chief Financial Officer at Senti Biosciences, Inc..

“Jay Cross was appointed as the Company’s Chief Financial Officer, effective as of March 3, 2025.”

Yvonne Li departed as Interim Chief Financial Officer at Senti Biosciences, Inc..

“On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.”

Senti Biosciences, Inc.: Filed Certificate of Designation with Delaware Secretary of State designating 21,200 shares of Series A Preferred Stock with stated value of $2,250.00 per share, setting forth rights, preferences and limitations (effective 2024-12-02).

“on December 2, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 21,200 shares of its authorized and unissued preferred stock as Series A Preferred Stock, each with a stated value of $2,250.00 per share”

Frances D. Schulz was appointed as Director at Senti Biosciences, Inc..

“On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.”

Omid Farokhzad resigned as Director at Senti Biosciences, Inc..

“On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.”

Kanya Rajangam was appointed as President at Senti Biosciences, Inc..

“Kanya Rajangam, M.D., Ph.D., the Company's Head of Research and Development, and Chief Medical Officer, was appointed to serve as the President of the Company, effective as of May 14, 2024”

Timothy Lu changed role as President at Senti Biosciences, Inc..

“Timothy Lu, M.D., Ph.D., Chief Executive Officer and President, stepped down as President”

Senti Biosciences, Inc. reported first quarter of 2024 results: net income Net loss was $12.1 million, or $0.26 per basic and diluted share, EPS $0.26 per basic and diluted share.

“Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”

Yvonne Li was appointed as Interim Chief Financial Officer at Senti Biosciences, Inc..

“Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024”

Timothy Lu was appointed as interim principal financial officer and principal accounting officer at Senti Biosciences, Inc..

“Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024”

Deborah Knobelman resigned as Chief Financial Officer, Treasurer and Head of Corporate Development at Senti Biosciences, Inc..

“On April 23, 2024, Deborah Knobelman, Ph.D., the Chief Financial Officer, Treasurer and Head of Corporate Development of Senti Biosciences Inc. (“the Company”) and its principal financial officer and principal accounting officer, notified the Company of her decision to resign from her employment with the Company, effective May 3, 2024.”

Senti Biosciences, Inc. reported the year ended December 31, 2023 results: net income Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for, EPS $0.42 per basic and diluted share (quarter) and $1.60 per share (year).

“On March 21, 2024, Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.”

Senti Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 6, 2024, the Staff granted the Company’s request for a second 180-calendar day period, or until August 5, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect with the open of business on Ja”

Senti Biosciences, Inc. announced a restructuring with charges of approximately $1 million (approximately 37%).

“On January 3, 2024, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved plans to streamline the Company’s business operations to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia and to continue support for the clinical development activities of SENTI-301A for the treatment of hepatocellular carcinoma in China through the Company’s partnership with Celest Therapeutics. Pursuant to these plans, the Company is reducing its workforce by approximately 37%. The Company expects that these resource allocation efforts, in addition to other expected receivables, will extend its cash runway into the first quarter of 2025. The Company expects to incur one-time estimated severance and related costs of approximately $1 million, which are anticipated to be incurred and recorded in the first quarter of 2024.”

Senti Biosciences, Inc. reported third quarter of 2023 results: net income 14.9, EPS 0.34.

“Net loss was $14.9 million, or $0.34 per basic and diluted share, for the quarter ended September 30, 2023, which included a non-recurring $21.7 million gain from discontinued operations, as well as a non-recurring $25.7 million impairment for leasehold improvements, both related to the GeneFab transaction.”

Senti Biosciences, Inc. entered into Collaboration and Option Agreement with Celest Therapeutics (Shanghai) Co. Ltd. (effective 2023-11-06).

“On November 6, 2023, Senti Biosciences, Inc. (the “ Company ”) entered into a Collaboration and Option Agreement (the “ Agreement ”) with Celest Therapeutics (Shanghai) Co. Ltd.”

Senti Biosciences, Inc. reported financial results for quarter ended June 30, 2023.

“On August 11, 2023, Senti Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.”

Senti Biosciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“August 7, 2023, Senti Biosciences, Inc. (the “ Company ” or “ Senti Bio ”) received written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive trading days, the closing bid price of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), had closed below the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). The Notice has no”

Senti Biosciences, Inc. completed a disposition involving GeneFab, LLC and Valere Bio, Inc. for $37.8 million in cash (closed 2023-08-07).

“”). Pursuant to the Agreement, Company sold the Purchased Assets, and consummated, or will consummate, the other transactions contemplated thereby, for total consideration of $37.8 million in cash (of which the amounts payable at closing of the transactions contemplated by the Agreement shall be subject to certain offsets against the advance payment under the DMSA”

Senti Biosciences, Inc. entered into Option Agreement with GeneFab, LLC valued at Up to $20 million for up to 19,633,444 shares at $1.01867 per share (effective 2023-08-07).

“In connection with the Agreement, the Company and GeneFab also entered into a letter agreement (the “ Option Agreement ”), pursuant to which GeneFab has the right to invest up to approximately $20 million to purchase up to 19,633,444 shares of the common stock of the Company, subject to approval by the Company’s stockholders to the extent required pursuant to applicable Nasdaq rules, at a price of $1.01867 per share in private placements in up to ten installments (the “ Option ”).”

Senti Biosciences, Inc. entered into Development and Manufacturing Services Agreement (DMSA) with GeneFab, LLC valued at Advance payment of $18.9 million and credit of $8 million for services (effective 2023-08-07).

“In connection with the Agreement, the Company and GeneFab entered into a development and manufacturing services agreement (the “ DMSA ”), pursuant to which GeneFab will provide to the Company certain research, development, and manufacturing services.”

Senti Biosciences, Inc. entered into Seller Economic Share Agreement (SESA) with GeneFab, LLC valued at 10% of realized gains of Valere from GeneFab distributions (effective 2023-08-07).

“In connection with the Agreement, the Company, GeneFab and Valere entered into a seller economic share agreement (the “ SESA ”), pursuant to which the Company will be entitled to receive ten percent of the realized gains of Valere arising and resulting from any cash or in-kind distributions from GeneFab in connection with the dividend or sale event, subject to the terms and conditions of the SESA.”

Senti Biosciences, Inc. entered into Framework Agreement with GeneFab, LLC valued at $37.8 million in cash and grant of Seller Economic Share (effective 2023-08-07).

“On August 7, 2023, Senti Biosciences, Inc. (the “ Company ”) entered into a framework agreement (the “ Agreement ”) with GeneFab, LLC, a Delaware limited liability company (“ GeneFab ”), and Valere Bio, Inc., a Delaware corporation and the parent company of GeneFab (“ Valere ”), which is wholly owned by a company managed by Celadon Partners, LLC, pursuant to which the Company, subject to the terms and conditions therein, (i) sold, assigned and transferred its rights, title and interest in certain of the assets and contractual rights to GeneFab, including all of Company’s equipment and leasehold improvements at the Company’s facilities in Alameda, California (the “ Alameda Facility ”) and certain of the Company's intellectual property related to the schematics for and design of the Alameda Facility, and (ii) subleased to GeneFab its premises under the lease for the Alameda Facility (a portion of which is subject to the satisfaction of certain conditions) (collectively, the “ Purchased A”

Philip Lee resigned as Chief Technology Officer at Senti Biosciences, Inc..

“On August 7, 2023, Philip Lee, Ph.D., the Company’s Chief Technology Officer, notified the Company of his resignation as an employee and as Chief Technology Officer of the Company, effective on August 7, 2023, to join GeneFab as its Chief Executive Officer.”

Senti Biosciences, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.

“2. Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain 34,350,453 60,890 54,266”

Senti Biosciences, Inc. shareholders approved Election of three Class I directors: Timothy Lu, M.D., Ph.D., Edward Mathers, and Omid Farokhzad, M.D. at the 2023-06-16 meeting.

“1. Election of directors: Name For Withheld Broker Non-Votes Timothy Lu, M.D., Ph.D. 32,295,728 81,697 2,088,184 Edward Mathers 22,511,863 9,865,562 2,088,184 Omid Farokhzad, M.D. 26,184,748 6,192,677 2,088,184”

Senti Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $18.7 million, EPS $0.42 per basic and diluted share.

“Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended March 31, 2023.”

David R. Epstein resigned as Director at Senti Biosciences, Inc..

“Mr. David R. Epstein, informed the board of directors (the “Board”) of Senti Biosciences, Inc. (“Senti”) of his intention to resign as a director of Senti, including resignation from all the committees of the Board on which he serves, effective as of the close of business on June 16, 2023.”

Senti Biosciences, Inc. reported the year ended December 31, 2022 results: net income Net loss ... $58.2 million, EPS $2.23 per share.

“Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.”

Senti Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.

“On November 10, 2022, Senti Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”

Curt A. Herberts III resigned as Chief Operating Officer at Senti Biosciences, Inc..

“On July 26, 2022, Curt A. Herberts III, the Chief Operating Officer of Senti Biosciences, Inc., a Delaware corporation (the “Company”), notified the Company of his decision to resign from his employment with the Company, effective as of August 19, 2022.”